Actively Recruiting
Neutrophil to Lymphocyte Ratio as a Marker of Severity and Prognosis in Hospitalized Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Led by Ain Shams University · Updated on 2025-08-15
190
Participants Needed
1
Research Sites
12 weeks
Total Duration
AI-Summary
What This Trial Is About
Chronic obstructive pulmonary disease COPD is a leading cause of death worldwide, with acute exacerbations AECOPD resulting in rapid worsening of respiratory function and disease status. Researchers are studying the neutrophil-to-lymphocyte ratio NLR, a blood marker reflecting inflammation, to see if it can predict severity, adverse outcomes, and treatment response in hospitalized patients with AECOPD. This observational study aims to clarify the usefulness of NLR in managing COPD exacerbations. The study involves measuring the neutrophil-to-lymphocyte ratio from blood tests of patients hospitalized with AECOPD. This ratio is calculated by dividing the number of neutrophils by the number of lymphocytes in the blood. Researchers will assess NLR at the baseline hospital admission and then again after three months to observe changes and potential links to disease severity and prognosis. Participants will be adults admitted to the Chest Department at Ain-Shams University Hospitals with AECOPD. The study includes collecting blood samples for complete blood counts to determine NLR, and monitoring clinical outcomes related to COPD exacerbation severity. The main outcome is the baseline NLR percentage, with a secondary outcome assessing NLR after three months. The study runs until March 2026, with no intervention treatments being tested as it is observational in nature.
CONDITIONS
Brief Title
Neutrophil to Lymphocyte Ratio in Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Research Team
H
Hieba G Ezzelregal, MD
M
mona A alhady, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here